Core Viewpoint - Sanara MedTech Inc. reported strong financial results for the fourth quarter and full year of 2025, achieving over $100 million in net revenue for the first time, with a year-over-year growth of 19% [5][17]. The company reaffirmed its revenue guidance for 2026, expecting growth of 13% to 17% [21]. Financial Summary - Fourth quarter 2025 net revenue was $27.5 million, a 5% increase from $26.3 million in the fourth quarter of 2024, driven by a $1.2 million increase in soft tissue repair products and a $49,000 increase in bone fusion products [8][9]. - Full year 2025 net revenue reached $103.1 million, up from $86.7 million in 2024, marking a 19% increase, with soft tissue repair products growing by 20% and bone fusion products by 12% [17][19]. Profitability Metrics - Adjusted EBITDA for the fourth quarter of 2025 was $4.7 million, compared to $4.1 million in the fourth quarter of 2024 [15]. For the full year, adjusted EBITDA was $17.0 million, up from $9.1 million in 2024 [19]. - Gross profit for the fourth quarter of 2025 was $25.7 million, a 7% increase from $24.1 million in the fourth quarter of 2024, with a gross margin of 93% [11]. Operational Developments - The company announced a strategic realignment, classifying the operations of Tissue Health Plus as discontinued operations [3][7]. - Sanara plans to introduce the OsStic™ Synthetic Injectable Structural Bio-Adhesive to the U.S. market in Q1 2027, pending FDA clearance [9]. - The BIASURGE product received an Innovative Technology contract from Vizient, enhancing its market access [9]. Cash Flow and Debt - Net cash provided by operating activities in the fourth quarter of 2025 was $3.9 million, compared to $0.9 million in the fourth quarter of 2024 [15]. - As of December 31, 2025, the company had $16.6 million in cash and $46.0 million in long-term debt, compared to $15.9 million and $30.7 million, respectively, as of December 31, 2024 [15]. Future Guidance - The company reaffirmed its financial guidance for 2026, expecting net revenue to range from $116 million to $121 million, representing a growth of approximately 13% to 17% compared to 2025 [21].

Core Viewpoint - Sanara MedTech Inc. will report its fourth quarter and full year 2025 financial results on March 24, 2026, before U.S. financial markets open [1] Group 1: Financial Reporting - The company will host a conference call and webcast on March 24, 2026, at 8:00 a.m. Eastern Time to discuss the financial results and hold a Q&A session [2] - A telephonic replay of the conference call will be available until April 7, 2026 [2] Group 2: Company Overview - Sanara MedTech Inc. focuses on developing and commercializing transformative technologies aimed at improving clinical outcomes and reducing healthcare costs in the surgical market [4] - The company markets and distributes various surgical products, including CellerateRX Surgical Activated Collagen Powder and FORTIFY TRG Tissue Repair Graft, primarily in the North American surgical tissue repair market [4] - Sanara aims to be an innovative provider of effective surgical solutions and is continually seeking to expand its offerings for patients in the United States [4]

Core Insights - Sanara MedTech Inc. is participating in the TD Cowen 46th Annual Health Care Conference from March 2 – 4, 2026, with a presentation scheduled for March 3 at 9:10 a.m. Eastern Time [1] Company Overview - Sanara MedTech Inc. focuses on developing and commercializing transformative technologies aimed at improving clinical outcomes and reducing healthcare costs in the surgical market [3] - The company markets surgical products primarily in the North American surgical tissue repair market, including CellerateRX Surgical Activated Collagen Powder, BIASURGE Advanced Surgical Solution, and FORTIFY TRG Tissue Repair Graft [3] - Sanara aims to be an innovative provider of effective surgical solutions and is committed to expanding its product offerings for patients in the United States [3]

Core Insights - Sanara MedTech's BIASURGE Advanced Surgical Solution has been awarded an Innovative Technology contract by Vizient, indicating its potential to improve healthcare outcomes and reduce costs in the surgical market [1][3][4] Company Overview - Sanara MedTech Inc. focuses on developing and commercializing transformative technologies aimed at improving clinical outcomes and reducing healthcare expenditures in the surgical market [7][8] - The company offers a range of surgical products, including BIASURGE, CellerateRX Surgical Activated Collagen Powder, and FORTIFY TRG Tissue Repair Graft, among others [8] Product Details - BIASURGE is a no-rinse irrigation solution designed for efficient surgical cleansing, featuring an antimicrobial preservative that provides broad-spectrum effectiveness against pathogenic microorganisms [5][6] - The product is optimized for pH, viscosity, and osmolality to ensure maximum performance while maintaining safety and effectiveness [5] - BIASURGE enhances surgical precision and visibility by maintaining a cleaner operative field, supporting infection-control strategies [6] Contract Significance - The Innovative Technology contract allows Vizient's extensive network of healthcare facilities to access BIASURGE at contracted pricing and pre-negotiated terms, effective January 1, 2026 [3][4] - The contract was awarded based on recommendations from hospital experts, highlighting BIASURGE's unique benefits over existing market products [3][4]

Core Insights - Sanara MedTech Inc. plans to launch OsStic Synthetic Injectable Structural Bio-Adhesive in the U.S. market in Q1 2027, following FDA clearance [1][2] - OsStic has received Breakthrough Device Designation from the FDA, indicating its potential to improve treatment for serious conditions [2] - The product is expected to be the first bone bioadhesive in the U.S. utilizing phosphoserine, α-TCP, and calcium silicate, offering significant advantages over traditional methods [2][3] Product Development and Regulatory Milestones - Sanara and Biomimetic Innovations Ltd (BMI) have achieved significant milestones in product development, clinical trials, and regulatory processes throughout 2025 [3] - The U.S. Patent and Trademark Office granted a patent for OsStic, ensuring protection of its key ingredients and applications until at least 2037 [3][6] - The partnership between Sanara and BMI includes an exclusive license and distribution agreement, enhancing Sanara's market position in orthopedic care [5][6] Market Need and Innovation - OsStic addresses critical limitations in current provisional fixation techniques, providing forty times stronger bonding than traditional calcium phosphate bone cement [2][3] - The product aims to meet the unmet clinical needs in complex joint reconstruction, offering a paradigm shift in treating previously non-repairable fractures [3] - Sanara's commitment to innovation is reflected in its collaboration with BMI to introduce OsStic as a new standard in bone bioadhesives [4]

Core Viewpoint - Sanara MedTech Inc. is participating in the Piper Sandler 37th Annual Healthcare Conference, presenting on December 3, 2025, to discuss its transformative technologies aimed at improving clinical outcomes and reducing healthcare costs in the surgical market [1] Company Overview - Sanara MedTech Inc. focuses on developing and commercializing technologies that enhance clinical outcomes while lowering healthcare expenditures in the surgical market [3] - The company markets and distributes a range of surgical products, including CellerateRX Surgical Activated Collagen Powder and FORTIFY TRG Tissue Repair Graft, primarily in the North American surgical tissue repair markets [3] - Sanara aims to be a leading provider of innovative surgical solutions and is committed to expanding its product offerings for patients in the United States [3]

Core Insights - Sanara MedTech Inc. has completed its evaluation of strategic alternatives for the Tissue Health Plus (THP) segment and has decided to discontinue THP operations to enhance operational efficiency and focus on its core surgical business [1][2] - The strategic realignment aims to allocate resources to areas with the highest expected returns, particularly the surgical business, which has shown consistent net revenue growth in recent years [2] - The winding down of THP is expected to continue through the end of 2025, with total cash investment in THP projected to be between $5.5 million and $6.5 million in the second half of 2025 [2] Company Overview - Sanara MedTech Inc. is a medical technology company focused on developing and commercializing technologies that improve clinical outcomes and reduce healthcare costs in the surgical market [3] - The company offers a range of surgical products, including CellerateRX Surgical Activated Collagen Powder and various advanced biologic products, primarily targeting the North American surgical tissue repair markets [3] - Sanara aims to be a leading provider of effective surgical solutions and is committed to expanding its product offerings to meet patient needs in the United States [3]